Brought to you by 
Roche licenses Antisoma's oncology compounds
Nov 2002
Executive Summary
Roche licensed worldwide exclusive rights to develop, manufacture, and sell several Antisoma anticancer compounds. The five-year deal provides Roche with Phase III ovarian cancer candidate pemtumomab, Phase I compounds Therex, TheraFab, and DMXAA, and several early-stage oncology candidates.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses Antisoma's oncology compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice